Genetic Testing for Cardiovascular
Conditions is an essential strategy
to better understand an individual’s risk
to develop potentially debilitating heart
and cardiovascular conditions.

Learning in advance if a patient is genetically predisposed to specific cardiovascular conditions and abnormalities is an important step to improve clinical management and inform a wide-range of lifestyle recommendations and interventions.

Breakthrough Genomics’ Offers 10 targeted Cardiovascular Focus Panels including:

  • Aorta Panel (covers 51 genes)
  • Arrhythmia Panel (covers 57 genes)
  • Atrial Fibrillation panel (covers 19 genes)
  • Brugada Syndrome Panel (covers 9 genes)
  • Cardiomyopathy Panel (covers 24 genes)
  • Congenital Structural Heart Diseases Panel (covers 62 genes)
  • Dilated Cardiomyopathy (DCM) Panel (covers 69 genes)
  • Short QT Syndrome (SQTS) Panel (covers 111 genes)
  • CPTV Panel (covers 9 genes)
  • ARVC Panel (covers 17 genes)

Breakthrough Genomics’ Comprehensive
Cardiovascular Test features accurate
analysis of nearly 200 genes that can impact cardiovascular health.

This test is recommended for individuals with a family-history of heart conditions of who are concerned about their long-term risk to develop heart diseases.

Benefits to genetic testing for cardiovascular conditions include:

  • informed recommendations for prevention and monitoring
  • improved clinical management decisions and treatment options
  • enhanced understanding of potential risk to family members
  • cost-savings by eliminating the need for unnecessary screening
    procedures and checkups
Genetic Risk Variants